After overhauling Amarin’s board earlier this year, activist investor Sarissa Capital has set its sights on Alkermes.
In a new letter to shareholders, the group is pressing Alkermes investors to vote for Sarissa’s board nominees and to vote against the company's planned compensation packages.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,